Gatifloxacin
Gatifloxacin, Zymaxid (gatifloxacin) is a small molecule pharmaceutical. Gatifloxacin was first approved as Zymar on 2003-03-28. It is used to treat bacterial conjunctivitis, bacterial infections, bacterial pneumonia, bronchitis, and cystitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Gatifloxacin, Zymaxid (discontinued: Gatifloxacin, Zymar)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gatifloxacin | ANDA | 2022-03-11 |
| pred-gati | unapproved drug other | 2018-02-22 |
| pred-gati-brom | unapproved drug other | 2018-02-22 |
| zymaxid | New Drug Application | 2016-09-26 |
Indications
FDA
EMA
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MA: Fluoroquinolone antibacterials, systemic
— J01MA16: Gatifloxacin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AE: Fluoroquinolone antiinfectives, ophthalmologic
— S01AE06: Gatifloxacin
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | — | 2 | 1 | — | 3 |
| Conjunctivitis | D003231 | HP_0000509 | H10 | — | — | 2 | 1 | — | 3 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | 1 | — | 2 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 1 | — | 2 |
| Eye infections | D015817 | EFO_1001888 | — | — | — | 1 | 1 | — | 2 |
| Microbial drug resistance | D004352 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Corneal ulcer | D003320 | — | H16.0 | — | 1 | — | — | — | 1 |
| Keratitis | D007634 | HP_0000491 | H16 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gatifloxacin |
| INN | gatifloxacin |
| Description | Gatifloxacin is a monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes. It has a role as an antiinfective agent, an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor and an antimicrobial agent. It is a quinolinemonocarboxylic acid, a N-arylpiperazine, an organofluorine compound, a quinolone and a quinolone antibiotic. |
| Classification | Small molecule |
| Drug class | antibacterials (quinolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12 |
Identifiers
| PDB | — |
| CAS-ID | 112811-59-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL31 |
| ChEBI ID | 5280 |
| PubChem CID | 5379 |
| DrugBank | DB01044 |
| UNII ID | 81485Y3A9A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Gatifloxacin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,626 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,063 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use